TORL Biotherapeutics, LLC

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Claudin 6 (CLDN6)Antibody–drug conjugate
Non-Small Cell Lung CancerOvarian Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Ixotatug vedotinPhase 2Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Est. primary completion 2027-10 · NCT06690775 · CT.gov ↗
What to watch
December 2027 (1)
Ixotatug vedotinPhase 1/2FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Est. primary completion 2027-12 · NCT07322094 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.